Review Article| Volume 42, ISSUE 4, P683-698, December 2015

Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?

  • Leo Han
    Corresponding author. Department of Obstetrics and Gynecology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Mailcode: L466, Portland, OR 97239.
    Department of Obstetrics and Gynecology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Search for articles by this author
  • Jeffrey T. Jensen
    Department of Obstetrics and Gynecology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
    Search for articles by this author
Published:September 16, 2015DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Obstetrics and Gynecology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mosher W.D.
        • Jones J.
        Use of contraception in the United States: 1982-2008.
        Vital Health Stat 23. 2010; : 1-44
        • White R.H.
        The epidemiology of venous thromboembolism.
        Circulation. 2003; 107: I4-I8
        • Heit J.A.
        The epidemiology of venous thromboembolism in the community.
        Arterioscler Thromb Vasc Biol. 2008; 28: 370-372
        • Beckman M.G.
        • Hooper W.C.
        • Critchley S.E.
        • et al.
        Venous thromboembolism.
        Am J Prev Med. 2010; 38: S495-S501
        • Kahn S.R.
        • Ducruet T.
        • Lamping D.L.
        • et al.
        Prospective evaluation of health-related quality of life in patients with deep venous thrombosis.
        Arch Intern Med. 2005; 165: 1173-1178
        • Heinemann L.A.J.
        • Dinger J.C.
        Range of published estimates of venous thromboembolism incidence in young women.
        Contraception. 2007; 75: 328-336
        • Lidegaard Ø.
        • Løkkegaard E.
        • Jensen A.
        • et al.
        Thrombotic stroke and myocardial infarction with hormonal contraception.
        N Engl J Med. 2012; 366: 2257-2266
      1. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
        Lancet. 1996; 348: 498-505
        • Margolis K.L.
        • Adami H.-O.
        • Luo J.
        • et al.
        A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women.
        Fertil Steril. 2007; 88: 310-316
        • Bitzer J.
        • Amy J.-J.
        • Beerthuizen R.
        • et al.
        Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism.
        J Fam Plann Reprod Health Care. 2013; 39: 156-159
      2. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
        Lancet. 1995; 346: 1575-1582
        • Jick H.
        • Jick S.S.
        • Gurewich V.
        • et al.
        Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
        Lancet. 1995; 346: 1589-1593
        • Bloemenkamp K.W.M.
        • Helmerhorst F.M.
        • Rosendaal F.R.
        • et al.
        Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
        Lancet. 1995; 346: 1593-1596
        • Spitzer W.O.
        • Lewis M.A.
        • Heinemann L.A.
        • et al.
        Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.
        BMJ. 1996; 312: 83-88
        • Lidegaard O.
        • Lokkegaard E.
        • Svendsen A.L.
        • et al.
        Hormonal contraception and risk of venous thromboembolism: national follow-up study.
        BMJ. 2009; 339: b2890
        • Stanczyk F.Z.
        All progestins are not created equal.
        Steroids. 2003; 68: 879-890
        • Stanczyk F.Z.
        • Hapgood J.P.
        • Winer S.
        • et al.
        Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.
        Endocr Rev. 2013; 34: 171-208
        • Oral Contraceptive and Hemostasis Study Group
        The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study.
        Contraception. 2003; 67: 173-185
        • Vandenbroucke J.P.
        • Koster T.
        • Rosendaal F.R.
        • et al.
        Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.
        Lancet. 1994; 344: 1453-1457
        • Kemmeren J.M.
        • Algra A.
        • Meijers J.C.M.
        • et al.
        Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial.
        Blood. 2004; 103: 927-933
        • Mantha S.
        • Karp R.
        • Raghavan V.
        • et al.
        Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis.
        BMJ. 2012; 345: e4944
        • Ansbacher R.
        The pharmacokinetics and efficacy of different estrogens are not equivalent.
        Am J Obstet Gynecol. 2001; 184: 255-263
        • Canonico M.
        • Oger E.
        • Plu-Bureau G.
        • et al.
        Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER Study.
        Circulation. 2007; 115: 840-845
        • Tchaikovski S.N.
        • Rosing J.
        Mechanisms of estrogen-induced venous thromboembolism.
        Thromb Res. 2010; 126: 5-11
        • Stanczyk F.Z.
        • Grimes D.A.
        Sex hormone-binding globulin: not a surrogate marker for venous thromboembolism in women using oral contraceptives.
        Contraception. 2008; 78: 201-203
        • Odlind V.
        • Milsom I.
        • Persson I.
        • et al.
        Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?.
        Acta Obstet Gynecol Scand. 2002; 81: 482-490
        • Lidegaard Ø.
        • Milsom I.
        • Geirsson R.T.
        • et al.
        Hormonal contraception and venous thromboembolism.
        Acta Obstet Gynecol Scand. 2012; 91: 769-778
        • Edelman A.
        • Jensen J.
        Obesity and hormonal contraception: safety and efficacy.
        Semin Reprod Med. 2012; 30: 479-485
        • Edelman A.
        Contraceptive considerations in obese women.
        Contraception. 2009; 80: 583-590
        • Shapiro S.
        • Dinger J.
        Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies.
        J Fam Plann Reprod Health Care. 2010; 36: 33-38
        • Okoroh E.M.
        • Hooper W.C.
        • Atrash H.K.
        • et al.
        Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003–2008.
        Am J Obstet Gynecol. 2012; 207: 377.e1-377.e8
        • Bird S.T.
        • Hartzema A.G.
        • Brophy J.M.
        • et al.
        Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis.
        Can Med Assoc J. 2013; 185: E115-E120
        • Bloemenkamp K.W.M.
        • Helmerhorst F.M.
        • Rosendaal F.R.
        • et al.
        Thrombophilias and gynaecology.
        Best Pract Res Clin Obstet Gynaecol. 2003; 17: 509-528
        • Hatcher R.A.
        • Trussell J.
        • Nelson A.L.
        Contraceptive technology.
        Ardent Media, New York2008
        • Wells P.
        • Anderson D.
        The diagnosis and treatment of venous thromboembolism.
        Hematology Am Soc Hematol Educ Program. 2013; 2013: 457-463
        • Suissa S.
        • Blais L.
        • Spitzer W.O.
        • et al.
        First-time use of newer oral contraceptives and the risk of venous thromboembolism.
        Contraception. 1997; 56: 141-146
        • Dinger J.C.
        • Heinemann L.A.J.
        • Kühl-Habich D.
        The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on Oral Contraceptives based on 142,475 women-years of observation.
        Contraception. 2007; 75: 344-354
        • Dinger J.
        • Bardenheuer K.
        • Heinemann K.
        Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives.
        Contraception. 2014; 89: 253-263
        • Speroff L.
        • Darney P.D.
        A clinical guide for contraception.
        Lippincott Williams & Wilkins, Philadelphia2010
        • Suissa S.
        • Spitzer W.O.
        • Rainville B.
        • et al.
        Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.
        Hum Reprod. 2000; 15: 817-821
        • Jensen J.T.
        • Burke A.E.
        • Barnhart K.T.
        • et al.
        Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis.
        Contraception. 2008; 78: 451-458
        • Heinemann L.A.J.
        • Lewis M.A.
        • Assmann A.
        • et al.
        Could preferential prescribing and referral behaviour of physicians explain the elevated thrombosis risk found to be associated with third generation oral contraceptives?.
        Pharmacoepidemiol Drug Saf. 1996; 5: 285-294
        • Herings R.
        • Urquhart J.
        • Leufkens H.
        Venous thromboembolism among new users of different oral contraceptives.
        Lancet. 1999; 354: 127-128
        • Farmer R.D.T.
        • Lawrenson R.A.
        Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany.
        Am J Obstet Gynecol. 1998; 179: s78-s86
        • Lewis M.A.
        • Heinemann L.A.J.
        • MacRae K.D.
        • et al.
        The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research.
        Contraception. 1996; 54: 5-13
        • Farmer R.
        • Lawrenson R.
        • Thompson C.
        • et al.
        Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
        Lancet. 1997; 349: 83-88
        • Jick S.S.
        • Hernandez R.K.
        Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data.
        BMJ. 2011; 342: d2151
        • Parkin L.
        • Sharples K.
        • Hernandez R.K.
        • et al.
        Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database.
        BMJ. 2011; 342: d2139
        • Van Hylckama Vlieg A.
        • Helmerhorst F.M.
        • Vandenbroucke J.P.
        • et al.
        The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study.
        BMJ. 2009; 339: b2921
      3. Research C for DE and. Drug Safety and Availability - FDA drug safety communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone. Available at: Accessed March 3, 2015.

        • Van den Heuvel M.W.
        • van Bragt A.J.M.
        • Alnabawy A.K.M.
        • et al.
        Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive.
        Contraception. 2005; 72: 168-174
        • Jick S.
        • Kaye J.A.
        • Li L.
        • et al.
        Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 μg of ethinyl estradiol.
        Contraception. 2007; 76: 4-7
        • Jick S.S.
        • Hagberg K.W.
        • Hernandez R.K.
        • et al.
        Postmarketing study of ORTHO EVRA® and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism.
        Contraception. 2010; 81: 16-21
        • Jick S.S.
        • Kaye J.A.
        • Russmann S.
        • et al.
        Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 μg of ethinyl estradiol.
        Contraception. 2006; 73: 223-228
        • Dore D.D.
        • Norman H.
        • Loughlin J.
        • et al.
        Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users.
        Contraception. 2010; 81: 408-413
        • Cole J.A.
        • Norman H.
        • Doherty M.
        • et al.
        Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users.
        Obstet Gynecol. 2007; 109: 339-346
        • Lidegaard Ø.
        • Nielsen L.H.
        • Skovlund C.W.
        • et al.
        Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10.
        BMJ. 2012; 344: e2990
      4. US Food and Drug Administration, Office of Surveillance and Epidemiology. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints. Available at: Accessed May 21, 2015.

        • Johnson J.V.
        • Lowell J.
        • Badger G.J.
        • et al.
        Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial.
        Obstet Gynecol. 2008; 111: 278-284
        • White T.
        • Ozel B.
        • Jain J.K.
        • et al.
        Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins.
        Contraception. 2006; 74: 293-296
        • Schulz K.F.
        • Grimes D.A.
        The Lancet handbook of essential concepts in clinical research.
        Elsevier, Philadelphia2006
        • Dinger J.
        • Möhner S.
        • Heinemann K.
        Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring.
        Obstet Gynecol. 2013; 122: 800-808
        • Reid R.L.
        • Westhoff C.
        • Mansour D.
        • et al.
        Oral Contraceptives and venous thromboembolism consensus opinion from an International Workshop held in Berlin, Germany in December 2009.
        J Fam Plann Reprod Health Care. 2010; 36: 117-122
        • Vessey M.
        • Yeates D.
        • Flynn S.
        Factors affecting mortality in a large cohort study with special reference to oral contraceptive use.
        Contraception. 2010; 82: 221-229
      5. WHO. Medical eligibility criteria for contraceptive use. WHO. Available at: Accessed May 18, 2015.

      6. CDC - United States medical eligibility criteria (USMEC) for contraceptive use - reproductive health. Available at: Accessed July 28, 2014.

      CHORUS Manuscript

      View Open Manuscript